Phase 2 Trial of NeuVax Vaccine for HER2-positive DCIS Fully Enrolled, Sellas Announces
News
The Phase 2 trial evaluating Sellas Life Sciences‘ cancer vaccine NeuVax as a treatment for women with early stage HER2-positive ductal carcinoma in situ (DCIS), a non-invasive breast cancer, has completed ... Read more